One in three young people estimated to live with pediatric onset chronic conditions

Lex­i­con Phar­ma­ceu­ti­cals is prepar­ing to re­sub­mit its type 1 di­a­betes drug can­di­date to the FDA af­ter its first at­tempt at ap­proval was met with a

AlloVir is lay­ing off 95% of its work­ers to “re­duce costs and pre­serve cap­i­tal” af­ter dis­con­tin­u­ing three Phase III tri­als of its an­tivi­ral cell ther­a­py